Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

Depression Clinical Trial

— RCC2  

Official title:

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02761330
• Other study ID #: 201512110
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: September 11, 2019

Study information

• Verified date: June 2021
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.

Description:

Seizures are often associated with loss of consciousness, possibly through effects on sub-cortical arousal systems, disruption of cortical-subcortical interactions, and ultimately through depressed neocortical function. Furthermore, people are often confused in the post-ictal state even when consciousness returns after a seizure. Disrupted cognitive function during the postictal phase has not been fully characterized but presents short and long-term implications. Many experience an acute disorder of attention, consciousness, and cognition, referred to as delirium. Memory deficits are also common. The neurobiology for these phenomena are incomplete and challenging to test, as seizures are typically sporadic and vary in intensity and character. In contrast, the setting of electroconvulsive therapy (ECT) provides the opportunity to study the reconstitution of consciousness and cognition following seizures in an elective and predictable context.

There is no standard agent used to induce general anesthesia during ECT. Ketamine is receiving greater attention as an infusion for treating depression and for its potential benefits on improving ECT efficacy and expediting cognitive recovery. Further data are needed to determine whether ketamine may improve recovery of cognitive function relative to etomidate, a commonly used anesthetic for general anesthesia during ECT.

The investigators will evaluate the cognition function and electroencephalographic patterns that accompany the recovery from ECT and general anesthesia. Twenty patients with refractory depression will be randomized in this interventional single-blinded randomized crossover trial. Each patient will complete seven study visits. The first visit will be conducted during the dose-charge titration ECT treatment with etomidate anesthesia. After this session, patients will be randomized to three sessions each week for two weeks (six treatments total). Over the first week patients will be randomized in order for three treatment arms: (1) etomidate general anesthesia and ECT, (2) ketamine general anesthesia and ECT, and (3) ketamine alone. Patients will be blinded to the treatment arm for each session. Baseline and post-treatment measurements of cognition and ECT will be acquired on each of the six treatment sessions.

Patients that agree will have a MRI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: September 11, 2019
• Est. primary completion date: September 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Treatment resistant depression requiring outpatient ECT

• Planned right unilateral ECT stimulation

• English speaking

• Able to provide written informed consent

Exclusion Criteria:

• Known brain lesion or neurological illness that causes cognitive impairment

• Schizophrenia

• Schizoaffective disorder

• Blindness or deafness or motor impediments that may impair performance for cognitive testing battery

• Inadequate ECT seizure duration with etomidate

Related Conditions & MeSH terms

• Cognition Disorders
• Cognitive Disorders
• Delirium
• Depression
• Seizures

Intervention

Drug:
• Ketamine
Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.

Procedure:
• Electroconvulsive Therapy
Dose of the ECT charge will be determined during titration session prior to randomization.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	James S McDonnell Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Cognitive Function During Recovery: Rate of Recovery	A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses.; Cognition Test Battery: Psychomotor Vigilance Task (PVT); Digital Symbol Substitution Task (DSST); Motor Praxis Task (MP); Visual Object Learning Task (VOLT); Abstract Matching (AM); Rate of Recovery for this measure is defined as the time (in inverse hours) for participants to return to their baseline performance for each task.	0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Primary	Change in Cognitive Function During Recovery: Initial Decrement	A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses.; Cognition Test Battery: Psychomotor Vigilance Task (PVT); Digital Symbol Substitution Task (DSST); Motor Praxis Task (MP); Visual Object Learning Task (VOLT); Abstract Matching (AM); Initial Decrement for this measure is defined as the difference between response times (in seconds) at baseline and t=0 for each task.	0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Secondary	Delirium Incidence and Severity	Assessed using 3D Confusion Assessment Method (CAM).; The groups/arms for this outcome are separated by anesthetic regimen; however, due to the crossover design of this study all participants are included in analyses for each group.	Immediately following return of consciousness (t=0) during treatment days 1-6.
Secondary	Suicidality	The groups/arms for this outcome are combined as a whole-group analysis due to the crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. All participants included in analyses completed all treatments, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in suicidality from baseline to treatment 6 based on the Scale of Suicide Ideation.; The measure completed was the Scale of Suicide Ideation. For this study, participants completed the following questions of the questionnaire: wish to live (0 Moderate to Strong, 1 Weak, 2 None); wish to die (0 None, 1 Weak, 2 Moderate to Strong); The total scores range from 0-4. Lower scores indicate high suicide ideation, and high scores indicate low suicide ideation.	assessed at baseline on treatment days 1-6.
Secondary	ECT Seizure Duration	Duration (in seconds) of seizure induced by ECT treatment	up to days 1-6
Secondary	ECT Electrical Dose	The electrical dose necessary for seizure induction is determined during a dose-charge titration session prior to participant randomization and session 1. These results report the average electrical dose across all participants for the first treatment session during Treatment Week 1.; The range for these data is 0 - 100% electrical charge.	First ECT treatment session during Treatment Week 1
Secondary	Subjective Assessment of Whether ECT Was Performed, Determined by Asking the Patient.	To assess patient blinding of treatment performed, the patient will be asked: "Based on how you feel, did you have ECT today?"; Results indicate participants correctly answering the subjective assessment.	Assessed at 120 minutes after return of responsiveness on treatment days 1-6
Secondary	Change in Mood Assessed Using the Mood Self-Assessment Manikin	Mood Self-Assessment Manikin (SAM) Scale: 1 (very unpleasant) - 9 (very pleasant).; The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the SAM. Additionally, data collected at baseline are not dependent on the study group/arm.	baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Secondary	Average Change in Mood Based on the Depression PROMIS-CAT	PROMIS-CAT (Patient Reported Outcomes Measurement Information System-Computer Adaptive Testing) for depression; The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the PROMIS-CAT. Additionally, data collected at baseline are not dependent on the study group/arm.	baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Secondary	Change in Delta Band (0.5-4 Hz) Relative Power in the Scale EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the delta band over the sum of total power between 0.5 - 70Hz.	baseline, post-ECT from 0-120 minutes
Secondary	Change in Theta Band (4-8 Hz) Relative Power in the Scalp EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the theta band over the sum of total power between 0.5 - 70Hz.	baseline, post-ECT from 0-120 minutes
Secondary	Change in Alpha Band (8-13 Hz) Power in the Scalp EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the alpha band over the sum of total power between 0.5 - 70Hz.	baseline, post-ECT from 0-120 minutes
Secondary	Change in Beta Band (13-20 Hz) Relative Power in the Scalp EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the beta band over the sum of total power between 0.5 - 70Hz.	baseline, post-ECT from 0-120 minutes
Secondary	Change in Anterior-Posterior Functional Connectivity in the Scalp During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the coherence measure, which is used for tracking changes in anterior-posterior functional connectivity.; Coherence is a measure of synchronization between two signals which is used to measure anterior-posterior functional connectivity. Coherence is a unitless measure between 0 and 1. High coherence between time-series of two neural populations reflects higher efficiency in communication between those populations and therefore stronger functional connectivity.	baseline, post-ECT from 0-120 minutes
Secondary	Change in Anterior-Posterior Phase-lag in the Scalp EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Phase-lag was assessed using the Phase-Lag Index (PLI), a measure ranging from 0 - 1. A consistent phase-lag between two tim-series results in a PLI of 1. A time-series without coupling results in a PLI near or equaling 0. Results show the difference in anterior-posterior PLI between baseline and post-ECT.	baseline, post-ECT from 0 -120 minutes
Secondary	Change in EEG Entropy in the Scalp EEG During Recovery	High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as permutation entropy (PE) measures in posterior regions, which we are using to track changes in scalp EEG entropy.; Permutation Entropy (PE) is a measure that is used to quantify the complexity of time series signals. It is a unitless measure between 0 and 1. Lower the PE represents a more regular and more deterministic time series while higher PE represents a more complex time series.	baseline, Post-ECT from 0 -120 minutes